Heartseed

iPS-cell-derived cardiomyocyte spheroid therapy

219A · TSE · Japan

Public Market Listing

219ATSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Heartseed are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Cardiac cell therapyCell therapy
Heart Failure

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 August 2026Topline resultHS-001LAPiS Phase 1/2 (NCT04945018) 52-week topline results presented at ESC Congress 2026
Heartseed Inc. · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$3.0M—$40M$0.4Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$20M—$44M—report ↗

Heartseed reported revenue of $20.22M and cash and equivalents of $43.65M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$5.8M—$35M$5.4Mreport ↗